<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NAROPIN- ropivacaine hydrochloride injection </strong><br>Fresenius Kabi USA, LLC<br></p></div>
<h1>Naropin (ropivacaine HCl Injection USP)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="dd903bdd-b86a-45c3-b406-4364ed9ac56e"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First">Rx only</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="df3e0ef0-6184-42d1-8143-e6c0f330a9f0"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION:</h1>
<p class="First">Naropin<span class="Sup">®</span> Injection contains ropivacaine HCl which is a member of the amino amide class of local anesthetics.  Naropin Injection is a sterile, isotonic solution that contains the enantiomerically pure drug substance, sodium chloride for isotonicity and Water for Injection. Sodium hydroxide and/or hydrochloric acid may be used for pH adjustment.  It is administered parenterally.</p>
<p>Ropivacaine HCl is chemically described as S-(-)-1-propyl-2',6'-pipecoloxylidide hydrochloride monohydrate.  The drug substance is a white crystalline powder, with the following structural formula:</p>
<p> <img alt="structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=56dfabf7-f7a8-4601-b17a-cb16fb995b0f&amp;name=naropin-figure-1-narop-struc.jpg"></p>
<p>At 25°C ropivacaine HCl has a solubility of 53.8 mg/mL in water, a distribution ratio between n-octanol and phosphate buffer at pH 7.4 of 14:1 and a pKa of 8.07 in 0.1 M KCl solution.  The pKa of ropivacaine is approximately the same as bupivacaine (8.1) and is similar to that of mepivacaine (7.7).  However, ropivacaine has an intermediate degree of lipid solubility compared to bupivacaine and mepivacaine.</p>
<p>Naropin Injection is preservative-free and is available in single dose containers in 2 (0.2%), 5 (0.5%), 7.5 (0.75%) and 10 mg/mL (1%) concentrations.  The specific gravity of Naropin Injection solutions range from 1.002 to 1.005 at 25°C.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ad8ce03d-802d-42d0-ab9f-9a1cafe281db"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY:</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="f0ee137f-29d6-4904-89d8-b6ed9fdcbff6"></a><a name="section-3.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Ropivacaine is a member of the amino amide class of local anesthetics and is supplied as the pure S-(-)-enantiomer.  Local anesthetics block the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential.  In general, the progression of anesthesia is related to the diameter, myelination and conduction velocity of affected nerve fibers.  Clinically, the order of loss of nerve function is as follows: (1) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, (2) temperature, (3) touch, (4) proprioception, and (5) skeletal muscle tone.</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ea8c72c5-d896-42e0-8354-7baf0b3a42ac"></a><a name="section-4"></a><p></p>
<h1>PHARMACOKINETICS:</h1>
<div class="Section" data-sectionCode="43682-4">
<a name="c244d42a-22b4-4db5-8576-e1536a719355"></a><a name="section-4.1"></a><p></p>
<h2>Absorption</h2>
<p class="First">The systemic concentration of ropivacaine is dependent on the total dose and concentration of drug administered, the route of administration, the patient's hemodynamic/circulatory condition, and the vascularity of the administration site.</p>
<p>From the epidural space, ropivacaine shows complete and biphasic absorption.  The half-lives of the 2 phases, (mean ± SD) are 14 ± 7 minutes and 4.2 ± 0.9 h, respectively.  The slow absorption is the rate limiting factor in the elimination of ropivacaine that explains why the terminal half-life is longer after epidural than after intravenous administration.  Ropivacaine shows dose-proportionality up to the highest intravenous dose studied, 80 mg, corresponding to a mean ± SD peak plasma concentration of 1.9 ± 0.3 mcg/mL.</p>
<p> </p>
<p>  </p>
<a name="b8448afa-580e-44b9-8e2d-df64a108b5de"></a><table width=" 710px">
<caption><span>Table 1 Pharmacokinetic (plasma concentration-time) data from clinical trials </span></caption>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left">  Route</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">Epidural Infusion*     </td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">Epidural</p>
                Infusion*     </td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">Epidural</p>
                Block<span class="Sup">†</span>     </td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">Epidural</p>
                Block<span class="Sup">†</span>     </td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">Plexus</p>
                Block<span class="Sup">‡</span>     </td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">IV</p>
                Infusion<span class="Sup">§</span>     </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  Dose (mg) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">1493 ± 10 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">2075 ± 206 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">1217 ± 277 </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 150</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 187.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 300</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 40</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  N</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 12</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 12</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 11</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 8</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 8</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 10</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 12</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  C<span class="Sub">max</span> (mg/L) </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">2.4 ± 1<span class="Sup">¶</span>     </td>
<td class="Botrule Lrule Rrule Toprule" align="center">2.8 ± 0.5<span class="Sup">¶</span>      </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">2.3 ± 1.1<span class="Sup">¶</span>     </td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.1 ± 0.2 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.6 ± 0.6 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">2.3 ± 0.8 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.2 ± 0.2<span class="Sup">#</span>     </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  T<span class="Sub">max</span> (min) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">n/a<span class="Sup">♠</span>     </td>
<td class="Botrule Lrule Rrule Toprule" align="center">n/a </td>
<td class="Botrule Lrule Rrule Toprule" align="center">n/a </td>
<td class="Botrule Lrule Rrule Toprule" align="center">43 ± 14 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">34 ± 9 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">54 ± 22 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">n/a </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">  AUC<span class="Sub">0-</span></p>
                (mg.h/L) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">135.5 ± 50 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">145 ± 34 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">161 ± 90 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">7.2 ± 2 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">11.3 ± 4 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">13 ± 3.3 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.8 ± 0.6 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  CL (L/h) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">11.03 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">13.7 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">n/a </td>
<td class="Botrule Lrule Rrule Toprule" align="center">5.5 ± 2 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">5 ± 2.6 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">n/a </td>
<td class="Botrule Lrule Rrule Toprule" align="center">21.2 ± 7 </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left">  t<span class="Sub">1/2</span> (hr)♥   </td>
<td class="Botrule Lrule Rrule Toprule" align="center">5 ± 2.5 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">5.7 ± 3 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">6 ± 3 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">5.7 ± 2 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">7.1 ± 3 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">6.8 ± 3.2 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.9 ± 0.5 </td>
</tr>
</tbody>
</table>
<p>*Continuous 72 hour epidural infusion after an epidural block with 5 or 10 mg/mL.</p>
<p><span class="Sup">† </span>Epidural anesthesia with 7.5 mg/mL (0.75%) for cesarean delivery.</p>
<p><span class="Sup">‡ </span>Brachial plexus block with 7.5 mg/mL (0.75%) ropivacaine.</p>
<p>§ 20 minute IV infusion to volunteers (40 mg).</p>
<p>¶ C<span class="Sub">max </span>measured at the end of infusion (ie, at 72 hr).</p>
<p># C<span class="Sub">max </span>measured at the end of infusion (ie, at 20 minutes).</p>
<p>♠ n/a=not applicable</p>
<p>♥ t<span class="Sub">½</span> is the true terminal elimination half-life.  On the other hand, t<span class="Sub">½</span> follows absorption‑dependent elimination (flip-flop) after non-intravenous administration.</p>
<p> </p>
<p>In some patients after a 300 mg dose for brachial plexus block, free plasma concentrations of ropivacaine may approach the threshold for CNS  toxicity (see <span class="Bold"><span class="Emphasis"><a href="#f1dcc873-dfff-4c97-a13e-cd57d70204fa">PRECAUTIONS</a></span></span>).  At a dose of greater than 300 mg, for local infiltration, the terminal half-life may be longer (&gt;30 hours).</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="f46d9f53-8859-4d2f-bf73-8e2447596940"></a><a name="section-4.2"></a><p></p>
<h2>Distribution</h2>
<p class="First">After intravascular infusion, ropivacaine has a steady                                     state volume of distribution of 41 ± 7                                     liters.  Ropivacaine is 94% protein bound,                                     mainly to α<span class="Sub">1</span>-acid glycoprotein.  An                                     increase in total plasma concentrations during continuous                                     epidural infusion has been observed, related to a postoperative                                     increase of α<span class="Sub">1</span>-acid glycoprotein.                                      Variations in unbound, ie, pharmacologically active,                                     concentrations have been less than in total plasma                                     concentration.  Ropivacaine readily crosses the                                     placenta and equilibrium in regard to unbound concentration will                                     be rapidly reached (see <span class="Bold"><span class="Emphasis"><a href="#f1dcc873-dfff-4c97-a13e-cd57d70204fa">  PRECAUTIONS</a></span></span>, <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#e64bb618-1a74-46a7-be68-79baf9f7afd4">  Labor and Delivery</a></span></span></span>).</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="b663ab9e-832d-42bf-85e2-839d84673902"></a><a name="section-4.3"></a><p></p>
<h2>Metabolism</h2>
<p class="First">Ropivacaine is extensively metabolized in the liver,                                     predominantly by aromatic hydroxylation mediated by cytochrome                                     P4501A to 3-hydroxy ropivacaine.  After a single IV                                     dose approximately 37% of the total dose is excreted in                                     the urine as both free and conjugated 3-hydroxy                                     ropivacaine.  Low concentrations of 3-hydroxy                                     ropivacaine have been found in the plasma.  Urinary                                     excretion of the 4-hydroxy ropivacaine, and both the 3-hydroxy                                     N-de-alkylated (3-OH-PPX) and 4-hydroxy N-de-alkylated                                     (4-OH-PPX) metabolites account for less than 3% of the                                     dose.  An additional metabolite,                                     2-hydroxy-methyl-ropivacaine, has been identified but not                                     quantified in the urine.  The N-de-alkylated metabolite                                     of ropivacaine (PPX) and 3-OH-ropivacaine are the major                                     metabolites excreted in the urine during epidural                                     infusion.  Total PPX concentration in the plasma was                                     about half as that of total ropivacaine; however, mean unbound                                     concentrations of PPX were about 7 to 9 times higher than that                                     of unbound ropivacaine following continuous epidural infusion up                                     to 72 hours.  Unbound PPX, 3-hydroxy and 4-hydroxy                                     ropivacaine, have a pharmacological activity in animal models                                     less than that of ropivacaine.  There is no evidence of                                         <span class="Italics"><span class="Emphasis">in viv</span></span>o racemization in urine of ropivacaine.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="e943588e-9cbd-4f61-bbf3-342853bcc57f"></a><a name="section-4.4"></a><p></p>
<h2>Elimination</h2>
<p class="First">The kidney is the main excretory organ for most local                                     anesthetic metabolites.  In total, 86% of the                                     ropivacaine dose is excreted in the urine after intravenous                                     administration of which only 1% relates to unchanged                                     drug.  After intravenous administration ropivacaine has                                     a mean ± SD total plasma clearance of                                     387 ± 107 mL/min, an unbound plasma clearance                                     of 7.2 ± 1.6 L/min, and a renal clearance of 1 mL/min.                                      The mean ± SD terminal half-life is 1.8                                     ± 0.7 h after intravascular administration and 4.2                                     ± 1 h after epidural administration (see <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#c244d42a-22b4-4db5-8576-e1536a719355">  Absorption</a></span></span></span>).</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="eca4bfd4-4929-48b4-958c-50179d8e5381"></a><a name="section-4.5"></a><p></p>
<h2>Pharmacodynamics</h2>
<p class="First">Studies in humans have demonstrated that, unlike most other local anesthetics, the presence of epinephrine has no major effect on either the time of onset or the duration of action of ropivacaine.  Likewise, addition of epinephrine to ropivacaine has no effect on limiting systemic absorption of ropivacaine.</p>
<p>Systemic absorption of local anesthetics can produce effects on the central nervous and cardiovascular systems.  At blood concentrations achieved with therapeutic doses, changes in cardiac conduction, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitability</span>, refractoriness, contractility, and peripheral <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> have been reported.  Toxic blood concentrations depress cardiac conduction and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitability</span>, which may lead to <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>, <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span> and to <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, sometimes resulting in fatalities.  In addition, myocardial contractility is depressed and peripheral vasodilation occurs, leading to decreased <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> and arterial blood pressure.<br><br>
    Following systemic absorption, local anesthetics can produce central nervous system stimulation, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or both.  Apparent central stimulation is usually manifested as <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span> and <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">shivering</span>, progressing to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, followed by <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, progressing ultimately to <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>.  However, the local anesthetics have a primary depressant effect on the medulla and on higher centers.  The depressed stage may occur without a prior excited stage.<br><br>
    In 2 clinical pharmacology studies (total n=24) ropivacaine and bupivacaine were infused (10 mg/min) in human volunteers until the appearance of CNS symptoms, eg, visual or hearing disturbances, perioral <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> and others.  Similar symptoms were seen with both drugs. In 1 study, the mean ± SD maximum tolerated intravenous dose of ropivacaine infused (124 ± 38 mg) was significantly higher than that of bupivacaine (99 ± 30 mg) while in the other study the doses were not different (115 ± 29 mg of ropivacaine and 103 ± 30 mg of bupivacaine). In the latter study, the number of subjects reporting each symptom was similar for both drugs with the exception of <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">muscle twitching</span> which was reported by more subjects with bupivacaine than ropivacaine at comparable intravenous doses.  At the end of the infusion, ropivacaine in both studies caused significantly less <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of cardiac conductivity (less QRS widening) than bupivacaine.  Ropivacaine and bupivacaine caused evidence of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of cardiac contractility, but there were no changes in <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>.</p>
<p>Clinical data in one published article indicate that differences in various pharmacodynamic measures were observed with increasing age.  In one study, the upper level of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> increased with age, the maximum decrease of mean arterial pressure (MAP) declined with age during the first hour after epidural administration, and the intensity of motor blockade increased with age.  However, no pharmacokinetic differences were observed between elderly and younger patients.</p>
<p>In non-clinical pharmacology studies comparing ropivacaine and bupivacaine in several animal species, the cardiac toxicity of ropivacaine was less than that of bupivacaine, although both were considerably more toxic than lidocaine.  Arrhythmogenic and cardio-depressant effects were seen in animals at significantly higher doses of ropivacaine than bupivacaine.  The incidence of successful resuscitation was not significantly different between the ropivacaine and bupivacaine groups.</p>
<br>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="db358a5f-d9bd-4b95-a93b-338db52467c4"></a><a name="section-4.6"></a><p></p>
<h2>Clinical Trials</h2>
<p class="First">Ropivacaine was studied as a local anesthetic both for surgical anesthesia and for <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span> management (see <span class="Bold"><span class="Emphasis"><a href="#f5ebc1d7-2664-4513-83ff-f0620e8e02ef">DOSAGE AND ADMINISTRATION</a></span></span>).</p>
<p>The onset, depth and duration of sensory block are, in general, similar to bupivacaine. However, the depth and duration of motor block, in general, are less than that with bupivacaine.  <br><br><span class="Bold"><span class="Emphasis">Epidural Administration In Surgery<br></span></span>There were 25 clinical studies performed in 900 patients to evaluate Naropin epidural injection for general surgery.  Naropin was used in doses ranging from 75 to 250 mg. In doses of 100 to 200 mg, the median (1st to 3rd quartile) onset time to achieve a T10 sensory block was 10 (5 to 13) minutes and the median (1st to 3rd quartile) duration at the T10 level was 4 (3 to 5) hours (see <span class="Bold"><span class="Emphasis"><a href="#f5ebc1d7-2664-4513-83ff-f0620e8e02ef">DOSAGE AND ADMINISTRATION</a></span></span>).  Higher doses produced a more profound block with a greater duration of effect.<br><br><span class="Bold"><span class="Emphasis">Epidural Administration In Cesarean Section<br></span></span>A total of 12 studies were performed with epidural administration of Naropin for cesarean section.  Eight of these studies involved 218 patients using the concentration of 5 mg/mL (0.5%) in doses up to 150 mg. Median onset measured at T6 ranged from 11 to 26 minutes.  Median duration of sensory block at T6 ranged from 1.7 to 3.2 h, and duration of motor block ranged from 1.4 to 2.9 h.  Naropin provided adequate <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">muscle relaxation</span> for surgery in all cases. </p>
<p>In addition, 4 active controlled studies for cesarean section were performed in 264 patients at a concentration of 7.5 mg/mL (0.75%) in doses up to 187.5 mg.  Median onset measured at T6 ranged from 4 to 15 minutes.  Seventy-seven to 96% of Naropin-exposed patients reported no <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at delivery.  Some patients received other anesthetic, analgesic, or sedative modalities during the course of the operative procedure.<br><br><span class="Bold"><span class="Emphasis">Epidural Administration In Labor And Delivery<br></span></span>A total of 9 double-blind clinical studies, involving 240 patients were performed to evaluate Naropin for epidural block for management of labor <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.  When administered in doses up to 278 mg as intermittent injections or as a continuous infusion, Naropin produced adequate <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief.</p>
<p>A prospective meta-analysis on 6 of these studies provided detailed evaluation of the delivered newborns and showed no difference in clinical outcomes compared to bupivacaine.  There were significantly fewer instrumental deliveries in mothers receiving ropivacaine as compared to bupivacaine.</p>
<a name="acdb4003-447f-42ea-b6f9-625b6ab1ce75"></a><table>
<caption><span>Table 2 LABOR AND DELIVERY META-ANALYSIS: MODE OF DELIVERY </span></caption>
<tfoot><tr><td colspan="0" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>p=0.004 versus bupivacaine   </dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left"> <br>
                  Delivery Mode</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">
<p class="First">    Naropin    </p>
                    n=199    </td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">
<p class="First">Bupivacaine</p>
                n=188 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"> n</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> %</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> n</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> %</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  Spontaneous Vertex </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 116</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 58</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 92</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 49</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  Vacuum Extractor </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 26</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 33</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center">}27<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>      </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center">}40 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  Forceps</td>
<td class="Botrule Lrule Rrule Toprule" align="center">28</td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center">42</td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left">  Cesarean Section </td>
<td class="Botrule Lrule Rrule Toprule" align="center">29</td>
<td class="Botrule Lrule Rrule Toprule" align="center">15 </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 21</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 11</td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="Emphasis">Epidural Administration In <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">Postoperative Pain</span> Management</span></span><span class="Italics"><span class="Emphasis"> <br></span></span>There were 8 clinical studies performed in 382 patients to evaluate Naropin 2 mg/mL (0.2%) for <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">postoperative pain</span> management after upper and lower abdominal surgery and after orthopedic surgery.  The studies utilized intravascular morphine via PCA as a rescue medication and quantified as an efficacy variable. </p>
<p>Epidural anesthesia with Naropin 5 mg/mL, (0.5%) was used intraoperatively for each of these procedures prior to initiation of postoperative Naropin.  The incidence and intensity of the motor block were dependent on the dose rate of Naropin and the site of injection.  Cumulative doses of up to 770 mg of ropivacaine were administered over 24 hours (intraoperative block plus postoperative continuous infusion).  The overall quality of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief, as judged by the patients, in the ropivacaine groups was rated as good or excellent (73% to 100%).  The frequency of motor block was greatest at 4 hours and decreased during the infusion period in all groups.  At least 80% of patients in the upper and lower abdominal studies and 42% in the orthopedic studies had no motor block at the end of the 21-hour infusion period.  Sensory block was also dose rate-dependent and a decrease in spread was observed during the infusion period. <br><br>
    A double blind, randomized, clinical trial compared lumbar epidural infusion of Naropin (n=26) and bupivacaine (n=26) at 2 mg/mL (8 mL/h), for 24 hours after knee replacement.  In this study, the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> scores were higher in the Naropin group, but the incidence and the intensity of motor block were lower.</p>
<p>Continuous epidural infusion of Naropin 2 mg/mL (0.2%) during up to 72 hours for <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">postoperative pain</span> management after major abdominal surgery was studied in 2 multicenter, double-blind studies.  A total of 391 patients received a low thoracic epidural catheter, and Naropin 7.5 mg/L (0.75%) was given for surgery, in combination with GA.  Postoperatively, Naropin 2 mg/mL (0.2%), 4 to 14 mL/h, alone or with fentanyl 1, 2, or 4 mcg/mL was infused through the epidural catheter and adjusted according to the patient’s needs.  These studies support the use of Naropin 2 mg/mL (0.2%) for epidural infusion at 6 to 14 mL/h (12 to 28 mg) for up to 72 hours and demonstrated adequate <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> with only slight and nonprogressive motor block in cases of moderate to severe <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">postoperative pain</span>.<br><br>
    Clinical studies with 2 mg/mL (0.2%) Naropin have demonstrated that infusion rates of 6 to 14 mL (12 to 28 mg) per hour provide adequate <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> with nonprogressive motor block in cases of moderate to severe <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">postoperative pain</span>.  In these studies, this technique resulted in a significant reduction in patients’ morphine rescue dose requirement.  Clinical experience supports the use of Naropin epidural infusions for up to 72 hours.<br><br><span class="Bold"><span class="Emphasis">Peripheral Nerve Block<br></span></span>Naropin, 5 mg/mL (0.5%), was evaluated for its ability to provide anesthesia for surgery using the techniques of Peripheral Nerve Block.  There were 13 studies performed including a series of 4 pharmacodynamic and pharmacokinetic studies performed on minor nerve blocks.  From these, 235 Naropin-treated patients were evaluable for efficacy.  Naropin was used in doses up to 275 mg.  When used for brachial plexus block, onset depended on technique used.  Supraclavicular blocks were consistently more successful than axillary blocks.  The median onset of sensory block (anesthesia) produced by ropivacaine 0.5% via axillary block ranged from 10 minutes (medial brachial cutaneous nerve) to 45 minutes (musculocutaneous nerve).  Median duration ranged from 3.7 hours (medial brachial cutaneous nerve) to 8.7 hours (ulnar nerve).  The 5 mg/mL (0.5%) Naropin solution gave success rates from 56% to 86% for axillary blocks, compared with 92% for supraclavicular blocks.<br><br>
    In addition, Naropin, 7.5 mg/mL (0.75%), was evaluated in 99 Naropin-treated patients, in 2 double-blind studies, performed to provide anesthesia for surgery using the techniques of Brachial Plexus Block.  Naropin 7.5 mg/mL was compared to bupivacaine 5 mg/mL. In 1 study, patients underwent axillary brachial plexus block using injections of 40 mL (300 mg) of Naropin, 7.5 mg/mL (0.75%) or 40 mL injections of bupivacaine, 5 mg/mL (200 mg).  In a second study, patients underwent subclavian perivascular brachial plexus block using 30 mL (225 mg) of Naropin, 7.5 mg/mL (0.75%) or 30 mL of bupivacaine 5 mg/mL (150 mg).  There was no significant difference between the Naropin and bupivacaine groups in either study with regard to onset of anesthesia, duration of sensory blockade, or duration of anesthesia.<br><br>
    The median duration of anesthesia varied between 11.4 and 14.4 hours with both techniques.  In one study, using the axillary technique, the quality of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> and <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">muscle relaxation</span> in the Naropin group was judged to be significantly superior to bupivacaine by both investigator and surgeon.  However, using the subclavian perivascular technique, no statistically significant difference was found in the quality of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> and <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">muscle relaxation</span> as judged by both the investigator and surgeon.  The use of Naropin 7.5 mg/mL for block of the brachial plexus via either the subclavian perivascular approach using 30 mL (225 mg) or via the axillary approach using 40 mL (300 mg) both provided effective and reliable anesthesia.<br><br><span class="Bold"><span class="Emphasis">Local Infiltration<br></span></span>A total of 7 clinical studies were performed to evaluate the local infiltration of Naropin to produce anesthesia for surgery and <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> in <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">postoperative pain</span> management.  In these studies 297 patients who received Naropin in doses up to 200 mg (concentrations up to 5 mg/mL, 0.5%) were evaluable for efficacy.  With infiltration of 100 to 200 mg Naropin, the time to first request for analgesic was 2 to 6 hours.  When compared to placebo, Naropin produced lower <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> scores and a reduction of analgesic consumption.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="cb9f91c9-6449-4833-89ac-e369b08f10b0"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE:</h1>
<p class="First">Naropin is indicated for the production of local or regional                             anesthesia for surgery and for <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span> management.</p>
<p>Surgical Anesthesia: epidural block for surgery                             including cesarean section; major nerve block; local                             infiltration<br><span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">Acute Pain</span> Management: epidural continuous                             infusion or intermittent bolus, eg, postoperative or labor; local                             infiltration</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="a75e4392-944f-4c5c-8cdc-cb807d1b47b2"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS:</h1>
<p class="First">Naropin is contraindicated in patients with a known                             <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to ropivacaine or to any local anesthetic agent of the                             amide type.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="a02f7083-33d6-470f-98e6-d7b8ff56cb60"></a><a name="section-7"></a><p></p>
<h1>WARNINGS:</h1>
<p class="First">In performing Naropin blocks, unintended intravenous injection is                             possible and may result in <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span> or cardiac                             arrest.  The potential for successful resuscitation has not                             been studied in humans.  There have been rare reports of                             <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> during the use of Naropin for epidural anesthesia or                             peripheral nerve blockade, the majority of which occurred after                             unintentional accidental intravascular administration in elderly                             patients and in patients with concomitant heart disease.  In                             some instances, resuscitation has been difficult.  Should                             <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> occur, prolonged resuscitative efforts may be required to                             improve the probability of a successful outcome.<br><br>Naropin should be                             administered in incremental doses.  It is not recommended for                             emergency situations, where a fast onset of surgical anesthesia is                             necessary.  Historically, pregnant patients were reported to                             have a high risk for <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, cardiac/circulatory arrest and                             <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> when 0.75% bupivacaine (another member of the amino amide                             class of local anesthetics) was inadvertently rapidly injected                             intravenously.<br><br>Prior to receiving major blocks the general condition                             of the patient should be optimized and the patient should have an i.v.                             line inserted.  All necessary precautions should be taken to                             avoid intravascular injection.  Local anesthetics should only                             be administered by clinicians who are well versed in the diagnosis and                             management of dose-related toxicity and other acute emergencies which                             might arise from the block to be employed, and then only after ensuring                             the <span class="Bold"><span class="Emphasis">immediate (without delay)</span></span> availability of oxygen, other resuscitative drugs,                             cardiopulmonary resuscitative equipment, and the personnel resources                             needed for proper management of toxic reactions and related emergencies                             (see also <span class="Bold"><span class="Emphasis"><a href="#a48bb774-07e7-4a8d-9e1d-f6a0731bd93b">  ADVERSE                                         REACTIONS</a></span></span>, <span class="Bold"><span class="Emphasis"><a href="#f1dcc873-dfff-4c97-a13e-cd57d70204fa">  PRECAUTIONS</a></span></span>, and <span class="Bold"><span class="Emphasis"><a href="#b30561b1-dd28-4f46-808b-4eae6fbf8874">  MANAGEMENT OF LOCAL ANESTHETIC EMERGENCIES</a></span></span>).  Delay in proper management of dose-related                             toxicity, underventilation from any cause, and/or altered sensitivity                             may lead to the development of <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> and, possibly,                             <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  Solutions of Naropin should not be used for the                             production of obstetrical paracervical block anesthesia, retrobulbar                             block, or spinal anesthesia (subarachnoid block) due to insufficient                             data to support such use.  Intravenous regional anesthesia                             (bier block) should not be performed due to a lack of clinical                             experience and the risk of attaining toxic blood levels of                             ropivacaine.<br><br>It is essential that <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> for blood, or                             cerebrospinal fluid (where applicable), be done prior to injecting any                             local anesthetic, both the original dose and all subsequent doses, to                             avoid intravascular or subarachnoid injection.  However, a                             negative <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> does <span class="Italics"><span class="Emphasis">not</span></span> ensure against an intravascular or subarachnoid                             injection.<br><br>A well-known risk of epidural anesthesia may be an                             unintentional subarachnoid injection of local anesthetic.  Two                             clinical studies have been performed to verify the safety of Naropin at                             a volume of 3 mL injected into the subarachnoid space since this dose                             represents an incremental epidural volume that could be unintentionally                             injected.  The 15 and 22.5 mg doses injected resulted in                             sensory levels as high as T5 and T4, respectively.  Anesthesia                             to pinprick started in the sacral dermatomes in 2 to 3 minutes, extended                             to the T10 level in 10 to 13 minutes and lasted for approximately 2                             hours.  The results of these two clinical studies showed that a                             3 mL dose did not produce any serious adverse events when spinal                             anesthesia blockade was achieved.<br><br>Naropin should be used with                             caution in patients receiving other local anesthetics or agents                             structurally related to amide-type local anesthetics, since the toxic                             effects of these drugs are additive.<br><br>Patients treated with class III                             antiarrhythmic drugs (eg, amiodarone) should be under close surveillance                             and ECG monitoring considered, since cardiac effects may be                         additive.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="f1dcc873-dfff-4c97-a13e-cd57d70204fa"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS:</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="d25d6af3-0414-48e2-835c-521c029dd7d5"></a><a name="section-8.1"></a><p></p>
<h2>General</h2>
<p class="First">The safe and effective use of local anesthetics depends                                     on proper dosage, correct technique, adequate precautions and                                     readiness for emergencies.<br><br>Resuscitative equipment, oxygen                                     and other resuscitative drugs should be available for immediate                                     use (see <span class="Bold"><span class="Emphasis"><a href="#a02f7083-33d6-470f-98e6-d7b8ff56cb60">  WARNINGS</a></span></span> and <span class="Bold"><span class="Emphasis"><a href="#a48bb774-07e7-4a8d-9e1d-f6a0731bd93b">  ADVERSE REACTIONS</a></span></span>).  The lowest dosage that results in                                     effective anesthesia should be used to avoid high plasma levels                                     and serious adverse events.  Injections should be made                                     slowly and incrementally, with frequent <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspirations</span> before and                                     during the injection to avoid intravascular injection.                                      When a continuous catheter technique is used, syringe                                     <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspirations</span> should also be performed before and during each                                     supplemental injection.  During the administration of                                     epidural anesthesia, it is recommended that a test dose of a                                     local anesthetic with a fast onset be administered initially and                                     that the patient be monitored for central nervous system and                                     cardiovascular toxicity, as well as for signs of unintended                                     intrathecal administration before proceeding.  When                                     clinical conditions permit, consideration should be given to                                     employing local anesthetic solutions, which contain epinephrine                                     for the test dose because circulatory changes compatible with                                     epinephrine may also serve as a warning sign of unintended                                     intravascular injection.  An intravascular injection is                                     still possible even if <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspirations</span> for blood are                                     negative.  Administration of higher than recommended                                     doses of Naropin to achieve greater motor blockade or increased                                     duration of sensory blockade may result in cardiovascular                                     <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, particularly in the event of inadvertent                                     intravascular injection. Tolerance to elevated blood levels                                     varies with the physical condition of the patient.                                      Debilitated, elderly patients and acutely ill patients should be                                     given reduced doses commensurate with their age and physical                                     condition.  Local anesthetics should also be used with                                     caution in patients with <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span> or heart                                     block.<br><br>Careful and constant monitoring of cardiovascular and                                     respiratory vital signs (adequacy of ventilation) and the                                     patient's state of consciousness should be performed                                     after each local anesthetic injection.  It should be                                     kept in mind at such times that <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>,                                     incoherent speech, light-headedness, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> of                                     the mouth and lips, metallic taste, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, blurred                                     vision, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> may be                                     early warning signs of central nervous system                                     toxicity.  Because amide-type local anesthetics such as                                     ropivacaine are metabolized by the liver, these drugs,                                     especially repeat doses, should be used cautiously in patients                                     with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>.  Patients with severe hepatic                                     disease, because of their inability to metabolize local                                     anesthetics normally, are at a greater risk of developing toxic                                     plasma concentrations.  Local anesthetics should also                                     be used with caution in patients with impaired cardiovascular                                     function because they may be less able to compensate for                                     functional changes associated with the prolongation of A-V                                     conduction produced by these drugs.<br><br>Many drugs used during                                     the conduct of anesthesia are considered potential triggering                                     agents for <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span> (MH).  Amide-type                                     local anesthetics are not known to trigger this                                     reaction.  However, since the need for supplemental                                     general anesthesia cannot be predicted in advance, it is                                     suggested that a standard protocol for MH management should be                                     available.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="b5f47d78-931e-408f-b19c-0b86bfc91a15"></a><a name="section-8.2"></a><p></p>
<h2>Epidural Anesthesia</h2>
<p class="First">During epidural administration, Naropin should be                                     administered in incremental doses of 3 to 5 mL with sufficient                                     time between doses to detect toxic manifestations of                                     unintentional intravascular or intrathecal injection.                                      Syringe <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspirations</span> should also be performed before and during                                     each supplemental injection in continuous (intermittent)                                     catheter techniques.  An intravascular injection is                                     still possible even if <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspirations</span> for blood are                                     negative.  During the administration of epidural                                     anesthesia, it is recommended that a test dose be administered                                     initially and the effects monitored before the full dose is                                     given.  When clinical conditions permit, the test dose                                     should contain an appropriate dose of epinephrine to serve as a                                     warning of unintentional intravascular injection.  If                                     injected into a blood vessel, this amount of epinephrine is                                     likely to produce a transient "epinephrine response" within 45                                     seconds, consisting of an increase in heart rate and systolic                                     blood pressure, circumoral <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span> and <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>                                     in the unsedated patient.  The sedated patient may                                     exhibit only a pulse rate increase of 20 or more beats per                                     minute for 15 or more seconds.  Therefore, following                                     the test dose, the heart should be continuously monitored for a                                     heart rate increase.  Patients on beta-blockers may not                                     manifest changes in heart rate, but blood pressure monitoring                                     can detect a rise in systolic blood pressure.  A test                                     dose of a short-acting amide anesthetic such as lidocaine is                                     recommended to detect an unintentional intrathecal                                     administration.  This will be manifested within a few                                     minutes by signs of spinal block (eg, decreased sensation of the                                     buttocks, <span class="product-label-link" type="condition" conceptid="4154696" conceptname="Spastic paresis">paresis</span> of the legs, or, in the sedated patient,                                     absent knee jerk). An intravascular or subarachnoid injection is                                     still possible even if results of the test dose are                                     negative.  The test dose itself may produce a systemic                                     toxic reaction, high spinal or epinephrine-induced                                     cardiovascular effects.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="e6ba57fd-53ad-4bfb-8138-d38329066e30"></a><a name="section-8.3"></a><p></p>
<h2>Use in Brachial Plexus                                     Block</h2>
<p class="First">Ropivacaine plasma concentrations may approach the threshold for central nervous system toxicity after the administration of 300 mg of ropivacaine for brachial plexus block.  Caution should be exercised when using the 300 mg dose (see <span class="Bold"><span class="Emphasis"><a href="#ace320ff-63ee-4692-a46a-a39e03da5273">OVERDOSAGE</a></span></span>).</p>
<p>The dose for a major nerve block must be adjusted according to the site of administration and patient status.  Supraclavicular brachial plexus blocks may be associated with a higher frequency of serious adverse reactions, regardless of the local anesthetic used.</p>
<br>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="dd950f1b-58ad-41e6-9938-5d9a0f9d5c5c"></a><a name="section-8.4"></a><p></p>
<h2>Use in Peripheral Nerve                                     Block</h2>
<p class="First">Major peripheral nerve blocks may result in the                                     administration of a large volume of local anesthetic in highly                                     vascularized areas, often close to large vessels where there is                                     an increased risk of intravascular injection and/or rapid                                     systemic absorption, which can lead to high plasma                                     concentrations.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="a970235f-512d-4a39-a90d-2c808f158872"></a><a name="section-8.5"></a><p></p>
<h2>Use in Head and Neck                                     Area</h2>
<p class="First">Small doses of local anesthetics injected into the head                                     and neck area may produce adverse reactions similar to systemic                                     toxicity seen with unintentional intravascular injections of                                     larger doses.  The injection procedures require the                                     utmost care.  <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, respiratory                                     <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and/or <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, and cardiovascular                                     stimulation or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> have been reported.  These                                     reactions may be due to intra-arterial injection of the local                                     anesthetic with retrograde flow to the cerebral                                     circulation.  Patients receiving these blocks should                                     have their circulation and respiration monitored and be                                     constantly observed.  Resuscitative equipment and                                     personnel for treating adverse reactions should be immediately                                     available.  Dosage recommendations should not be                                     exceeded (see <span class="Bold"><span class="Emphasis"><a href="#f5ebc1d7-2664-4513-83ff-f0620e8e02ef">  DOSAGE AND ADMINISTRATION</a></span></span>).</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="d5897f59-df56-4413-bb47-47a20f26211b"></a><a name="section-8.6"></a><p></p>
<h2>Use in Ophthalmic                                     Surgery</h2>
<p class="First">The use of Naropin in retrobulbar blocks for ophthalmic                                     surgery has not been studied.  Until appropriate                                     experience is gained, the use of Naropin for such surgery is not                                     recommended.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="c6fd4c51-edda-4da6-94e4-49a174836726"></a><a name="section-8.7"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">When appropriate, patients should be informed in advance                                     that they may experience temporary <span class="product-label-link" type="condition" conceptid="4141128" conceptname="Absence of sensation">loss of sensation</span> and motor                                     activity in the anesthetized part of the body following proper                                     administration of lumbar epidural anesthesia.  Also,                                     when appropriate, the physician should discuss other information                                     including adverse reactions in the Naropin package                                 insert.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="a722d0f5-dc73-4c86-9bdd-1dce3cce2131"></a><a name="section-8.8"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Specific trials studying the interaction between                                     ropivacaine and class III antiarrhythmic drugs (eg, amiodarone)                                     have not been performed, but caution is advised (see <span class="Bold"><span class="Emphasis"><a href="#a02f7083-33d6-470f-98e6-d7b8ff56cb60">  WARNINGS</a></span></span>).<br><br>Naropin should be used with caution in patients                                     receiving other local anesthetics or agents structurally related                                     to amide-type local anesthetics, since the toxic effects of                                     these drugs are additive.  Cytochrome P4501A2 is                                     involved in the formation of 3-hydroxy ropivacaine, the major                                     metabolite.  <span class="Italics"><span class="Emphasis">In vivo</span></span>, the plasma clearance of ropivacaine was reduced by                                     70% during coadministration of fluvoxamine (25 mg bid                                     for 2 days), a selective and potent CYP1A2 inhibitor.                                      Thus strong inhibitors of cytochrome P4501A2, such as                                     fluvoxamine, given concomitantly during administration of                                     Naropin, can interact with Naropin leading to increased                                     ropivacaine plasma levels.  Caution should be exercised                                     when CYP1A2 inhibitors are coadministered.  Possible                                     interactions with drugs known to be metabolized by CYP1A2 via                                     competitive inhibition such as theophylline and imipramine may                                     also occur.  Coadministration of a selective and potent                                     inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with                                     ropivacaine infusion administered 1 hour after ketoconazole)                                     caused a 15% reduction in <span class="Italics"><span class="Emphasis">in vivo</span></span> plasma clearance of ropivacaine.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="a6108430-fb2b-493b-ac88-b5412550040e"></a><a name="section-8.9"></a><p></p>
<h2>Carcinogenesis, Mutagenesis,                                         Impairment of Fertility</h2>
<p class="First">Long term studies in animals of most local anesthetics, including ropivacaine, to evaluate the carcinogenic potential have not been conducted.</p>
<p>Weak mutagenic activity was seen in the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> test.  Mutagenicity was not noted in the other assays, demonstrating that the weak signs of <span class="Italics"><span class="Emphasis">in vitro</span></span> activity in the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> test were not manifest under diverse <span class="Italics"><span class="Emphasis">in vivo</span></span> conditions.<br><br>
    Studies performed with ropivacaine in rats did not demonstrate an effect on fertility or general reproductive performance over 2 generations.</p>
<br>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="bf76071b-cfa3-41ae-bebe-48986cf658d4"></a><a name="section-8.10"></a><p></p>
<h2>Pregnancy Category B</h2>
<p class="First">Reproduction toxicity studies have been performed in pregnant New Zealand white rabbits and Sprague-Dawley rats.  During gestation days 6 to 18, rabbits received 1.3, 4.2, or 13 mg/kg/day subcutaneously.  In rats, subcutaneous doses of 5.3, 11 and 26 mg/kg/day were administered during gestation days 6 to 15.  No teratogenic effects were observed in rats and rabbits at the highest doses tested.  The highest doses of 13 mg/kg/day (rabbits) and 26 mg/kg/day (rats) are approximately 1/3 of the maximum recommended human dose (epidural, 770 mg/24 hours) based on a mg/m<span class="Sup">2</span> basis.  In 2 prenatal and postnatal studies, the female rats were dosed daily from day 15 of gestation to day 20 postpartum.  The doses were 5.3, 11 and 26 mg/kg/day subcutaneously.  There were no treatment-related effects on late fetal development, parturition, lactation, neonatal viability, or growth of the offspring.<br><br>
    In another study with rats, the males were dosed daily for 9 weeks before mating and during mating.  The females were dosed daily for 2 weeks before mating and then during the mating, pregnancy, and lactation, up to day 42 post coitus.  At 23 mg/kg/day, an increased loss of pups was observed during the first 3 days postpartum.  The effect was considered secondary to impaired maternal care due to maternal toxicity.<br><br>
    There are no adequate or well-controlled studies in pregnant women of the effects of Naropin on the developing fetus.  Naropin should only be used during pregnancy if the benefits outweigh the risk.<br><br>
    <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">Teratogenicity</span> studies in rats and rabbits did not show evidence of any adverse effects on organogenesis or early fetal development in rats (26 mg/kg sc) or rabbits (13 mg/kg).  The doses used were approximately equal to total daily dose based on body surface area.  There were no treatment-related effects on late fetal development, parturition, lactation, neonatal viability, or growth of the offspring in 2 perinatal and postnatal studies in rats, at dose levels equivalent to the maximum recommended human dose based on body surface area.  In another study at 23 mg/kg, an increased pup loss was seen during the first 3 days postpartum, which was considered secondary to impaired maternal care due to maternal toxicity.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="e64bb618-1a74-46a7-be68-79baf9f7afd4"></a><a name="section-8.11"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">Local anesthetics, including ropivacaine, rapidly cross the placenta, and when used for epidural block can cause varying degrees of maternal, fetal and neonatal toxicity (see <span class="Bold"><span class="Emphasis"><a href="#ad8ce03d-802d-42d0-ab9f-9a1cafe281db">CLINICAL PHARMACOLOGY</a></span></span> and <span class="Bold"><span class="Emphasis"><a href="#ea8c72c5-d896-42e0-8354-7baf0b3a42ac">PHARMACOKINETICS</a></span></span>).  The incidence and degree of toxicity depend upon the procedure performed, the type and amount of drug used, and the technique of drug administration.  Adverse reactions in the parturient, fetus and neonate involve alterations of the central nervous system, peripheral vascular tone and cardiac function.<br><br>
    Maternal <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> has resulted from regional anesthesia with Naropin for obstetrical <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief. Local anesthetics produce vasodilation by blocking sympathetic nerves.  Elevating the patient's legs and positioning her on her left side will help prevent decreases in blood pressure.  The fetal heart rate also should be monitored continuously, and electronic fetal monitoring is highly advisable.  Epidural anesthesia has been reported to prolong the second stage of labor by removing the patient's reflex urge to bear down or by interfering with motor function.  Spontaneous vertex delivery occurred more frequently in patients receiving Naropin than in those receiving bupivacaine.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="c5fb6d55-3d1f-4468-b109-2f9edcae2b90"></a><a name="section-8.12"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Some local anesthetic drugs are excreted in human milk                                     and caution should be exercised when they are administered to a                                     nursing woman.  The excretion of ropivacaine or its                                     metabolites in human milk has not been studied.  Based                                     on the milk/plasma concentration ratio in rats, the estimated                                     daily dose to a pup will be about 4% of the dose given                                     to the mother.  Assuming that the milk/plasma                                     concentration in humans is of the same order, the total Naropin                                     dose to which the baby is exposed by breast-feeding is far lower                                     than by exposure <span class="Italics"><span class="Emphasis">in utero</span></span> in pregnant women at term (see <span class="Bold"><span class="Emphasis"><a href="#f1dcc873-dfff-4c97-a13e-cd57d70204fa">  PRECAUTIONS</a></span></span>).</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="e0792ceb-ab64-4304-a2d0-0026e6d18dd8"></a><a name="section-8.13"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The safety and efficacy of Naropin in pediatric patients                                     have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="cf83f26f-9585-4658-9198-4ea924b62898"></a><a name="section-8.14"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Of the 2,978 subjects that were administered Naropin                                     Injection in 71 controlled and uncontrolled clinical studies,                                     803 patients (27%) were 65 years of age or older which                                     includes 127 patients (4%) 75 years of age and                                     over.  Naropin Injection was found to be safe and                                     effective in the patients in these studies.  Clinical                                     data in one published article indicate that differences in                                     various pharmacodynamic measures were observed with increasing                                     age.  In one study, the upper level of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>                                     increased with age, the maximum decrease of mean arterial                                     pressure (MAP) declined with age during the first hour after                                     epidural administration, and the intensity of motor blockade                                     increased with age.<br><br>This drug and its metabolites are known                                     to be excreted by the kidney, and the risk of toxic reactions to                                     this drug may be greater in patients with impaired renal                                     function.  Elderly patients are more likely to have                                     decreased hepatic, renal, or cardiac function, as well as                                     concomitant disease.  Therefore, care should be taken                                     in dose selection, starting at the low end of the dosage range,                                     and it may be useful to monitor renal function (see <span class="Bold"><span class="Emphasis"><a href="#ea8c72c5-d896-42e0-8354-7baf0b3a42ac">  PHARMACOKINETICS</a></span></span>, <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#e943588e-9cbd-4f61-bbf3-342853bcc57f">  Elimination</a></span></span></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="a48bb774-07e7-4a8d-9e1d-f6a0731bd93b"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS:</h1>
<p class="First">Reactions to ropivacaine are characteristic of those associated with other amide-type local anesthetics.  A major cause of adverse reactions to this group of drugs may be associated with excessive plasma levels, which may be due to overdosage, unintentional intravascular injection or slow metabolic degradation.<br><br>
    The reported adverse events are derived from clinical studies conducted in the U.S. and other countries.  The reference drug was usually bupivacaine.  The studies used a variety of premedications, sedatives, and surgical procedures of varying length.  A total of 3,988 patients have been exposed to Naropin at concentrations up to 1% in clinical trials.  Each patient was counted once for each type of adverse event.</p>
<div class="Section" data-sectionCode="34084-4">
<a name="e5a0122e-13de-4523-ad4a-72d12e19fa1e"></a><a name="section-9.1"></a><p></p>
<h2>Incidence   ≥5%</h2>
<p class="First">For the indications of epidural administration in surgery, cesarean section, <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">postoperative pain</span> management, peripheral nerve block, and local infiltration, the following treatment-emergent adverse events were reported with an incidence of ≥ 5% in all clinical studies (N=3988): <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (37%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (24.8%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (11.6%), <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> (9.3%), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (9.2%), <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (8%), postoperative complications (7.1%), <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (6.1%), <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> (5.6%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (5.1%), <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (5.1%), and <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> (5%).</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="d2642ebc-ad7e-420c-9548-aeeeb3fc90bd"></a><a name="section-9.2"></a><p></p>
<h2>Incidence 1 to                                     5%</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary retention</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="e84b4078-3b20-4e10-bdc6-a7c1fd50b6d1"></a><a name="section-9.3"></a><p></p>
<h2>Incidence in Controlled Clinical                                         Trials</h2>
<p class="First">The reported adverse events are derived from controlled clinical studies with Naropin (concentrations ranged from 0.125% to 1% for Naropin and 0.25% to 0.75% for bupivacaine) in the U.S. and other countries involving 3094 patients.  Table 3A and 3B list adverse events (number and percentage) that occurred in at least 1% of Naropin-treated patients in these studies.  The majority of patients receiving concentrations higher than 5 mg/mL (0.5%) were treated with Naropin.</p>
<table>
<caption><span>Table 3A Adverse Events Reported in ≥1% of Adult Patients Receiving Regional or Local Anesthesia (Surgery, Labor, Cesarean Section, <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">Postoperative Pain</span> Management, Peripheral Nerve Block and Local Infiltration) </span></caption>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2"> <br><span class="Bold"><span class="Emphasis">  Adverse Reaction</span></span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"> 
                <p class="First"><span class="Bold"><span class="Emphasis">Naropin</span></span></p>
<span class="Bold"><span class="Emphasis">total N=1661</span></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"> 
                <p class="First"><span class="Bold"><span class="Emphasis">Bupivacaine</span></span></p>
<span class="Bold"><span class="Emphasis">total N=1433</span></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold"><span class="Emphasis">    N </span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<span class="Bold"><span class="Emphasis">(%) </span></span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <span class="Bold"><span class="Emphasis">N</span></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<span class="Bold"><span class="Emphasis">(%) </span></span> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  Hypotension </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  536 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">(32.3) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  408 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">(28.5) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  Nausea </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  283 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">(17) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  207 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">(14.4) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  Vomiting </td>
<td class="Botrule Lrule Rrule Toprule" align="center">117</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(7) </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 88</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(6.1) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  Bradycardia </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 96 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">(5.8) </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 73</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(5.1) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  Headache </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 84 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">(5.1) </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 68</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(4.7) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  Paresthesia </td>
<td class="Botrule Lrule Rrule Toprule" align="center">82</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(4.9) </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 57</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(4) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  Back pain </td>
<td class="Botrule Lrule Rrule Toprule" align="center">73</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(4.4) </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 75</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(5.2) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  Pain </td>
<td class="Botrule Lrule Rrule Toprule" align="center">71</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(4.3) </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 71</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(5) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  Pruritus </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 63 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">(3.8) </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 40</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(2.8) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  Fever </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 61 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">(3.7) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  37 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">(2.6) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  Dizziness </td>
<td class="Botrule Lrule Rrule Toprule" align="center">42</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(2.5) </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 23</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(1.6) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Rigors</span> (<span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span>) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">42</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(2.5) </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 24</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (1.7)  </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  Postoperative complications </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 41 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">(2.5) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  44 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">(3.1) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  Hypoesthesia </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 27 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">(1.6) </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 24</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(1.7) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  Urinary retention </td>
<td class="Botrule Lrule Rrule Toprule" align="center">23</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(1.4) </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 20</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(1.4) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  Progression of labor poor/failed           </td>
<td class="Botrule Lrule Rrule Toprule" align="center">23</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(1.4) </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 22</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(1.5) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  Anxiety </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 21 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">(1.3) </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 11</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(0.8) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast disorder</span>, breast-feeding </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 21 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">(1.3) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  12 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">(0.8) </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left">  Rhinitis </td>
<td class="Botrule Lrule Rrule Toprule" align="center">18 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">(1.1) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  13 </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (0.9)  </td>
</tr>
</tbody>
</table>
<table>
<caption><span>Table 3B  Adverse Events Reported in ≥1% of Fetuses or Neonates of Mothers Who Received Regional Anesthesia (Cesarean Section and Labor Studies) </span></caption>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2">  <span class="Bold"><span class="Emphasis">Adverse Reaction</span></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">
<p class="First"><span class="Bold"><span class="Emphasis">Naropin </span></span></p>
<span class="Bold"><span class="Emphasis">total N=639 </span></span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">
<p class="First"><span class="Bold"><span class="Emphasis">Bupivacaine </span></span></p>
<span class="Bold"><span class="Emphasis">total N=573 </span></span> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"> <span class="Bold"><span class="Emphasis">   N</span></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<span class="Bold"><span class="Emphasis">(%) </span></span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">  N </span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<span class="Bold"><span class="Emphasis">(%) </span></span> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  Fetal bradycardia </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  77</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(12.1) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">   68 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">(11.9) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  Neonatal jaundice </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  49 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">(7.7) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">   47 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">(8.2) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  Neonatal complication-NOS </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  42 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">(6.6) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">   38 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">(6.6) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  Apgar score low </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 18 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">(2.8) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  14 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">(2.4) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  Neonatal respiratory disorder      </td>
<td class="Botrule Lrule Rrule Toprule" align="center">17</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(2.7) </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 18</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(3.1) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  Neonatal tachypnea </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 14 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">(2.2) </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 15 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">(2.6) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  Neonatal fever </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 13 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">(2) </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 14 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">(2.4) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  Fetal  tachycardia </td>
<td class="Botrule Lrule Rrule Toprule" align="center">13</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(2) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">12</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(2.1) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  Fetal distress </td>
<td class="Botrule Lrule Rrule Toprule" align="center">11</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(1.7) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">10</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(1.7) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  Neonatal infection </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 10 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">(1.6) </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 8 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">(1.4) </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left">  Neonatal hypoglycemia </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 8 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">(1.3) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">16 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">(2.8) </td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ce39fb00-bb5d-42a1-b9a5-7054b7b52f1e"></a><a name="section-9.4"></a><p></p>
<h2>Incidence                                     &lt;1%</h2>
<p class="First">The following adverse events were reported during the Naropin clinical program in more than one patient (N=3988), occurred at an overall incidence of &lt;1%, and were considered relevant:<br><br><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">Application Site Reactions</span></span></span> - <span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">injection site pain</span><br><span class="Italics"><span class="Emphasis">Cardiovascular System</span></span> - <span class="product-label-link" type="condition" conceptid="4142895" conceptname="Near syncope">vasovagal reaction</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>, non-specific ECG abnormalities<br><span class="Italics"><span class="Emphasis">Female Reproductive</span></span> - poor progression of labor, <span class="product-label-link" type="condition" conceptid="4127206" conceptname="Uterus relaxed">uterine atony</span><br><span class="Italics"><span class="Emphasis">Gastrointestinal System</span></span> - <span class="product-label-link" type="condition" conceptid="197675" conceptname="Incontinence of feces">fecal incontinence</span>, tenesmus, neonatal <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span><br><span class="Italics"><span class="Emphasis">General and Other Disorders</span></span> - <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accident</span> and/or injury<br><span class="Italics"><span class="Emphasis">Hearing and Vestibular</span></span> - <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, hearing abnormalities<br><span class="Italics"><span class="Emphasis">Heart Rate and Rhythm</span></span> - <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">extrasystoles</span>, non-specific <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span><br><span class="Italics"><span class="Emphasis">Liver and Biliary System</span></span> - <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span><br><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="436670" conceptname="Metabolic disease">Metabolic Disorders</span></span></span> - <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span><br><span class="Italics"><span class="Emphasis">Musculoskeletal System</span></span> - <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span><br><span class="Italics"><span class="Emphasis">Myo/Endo/Pericardium</span></span> - ST segment changes, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span><br><span class="Italics"><span class="Emphasis">Nervous System</span></span> - <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, Horner’s syndrome, <span class="product-label-link" type="condition" conceptid="4154696" conceptname="Spastic paresis">paresis</span>, <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">hypokinesia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span>, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span><br><span class="Italics"><span class="Emphasis">Psychiatric Disorders</span></span> - <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span><br><span class="Italics"><span class="Emphasis">Respiratory System</span></span> - <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span><br><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">Skin Disorders</span></span></span> - <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span><br><span class="Italics"><span class="Emphasis">Urinary System Disorders</span></span> - <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>, micturition disorder<br><span class="Italics"><span class="Emphasis">Vascular</span></span> - <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>, <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span><br><span class="Italics"><span class="Emphasis">Vision</span></span> - vision abnormalities<br><br>
    For the indication epidural anesthesia for surgery, the 15 most common adverse events were compared between different concentrations of Naropin and bupivacaine.  Table 4 is based on data from trials in the U.S. and other countries where Naropin was administered as an epidural anesthetic for surgery.</p>
<table>
<caption><span>Table 4  Common Events (Epidural Administration) </span></caption>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left"> 
                <p class="First"><span class="Bold"><span class="Emphasis">Adverse</span></span></p>
<span class="Bold"><span class="Emphasis">Reaction</span></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="6">
<span class="Bold"><span class="Emphasis">Naropin </span></span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="4"><span class="Bold"><span class="Emphasis">Bupivacaine </span></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">
<p class="First"><span class="Bold"><span class="Emphasis">5 mg/mL </span></span></p>
<span class="Bold"><span class="Emphasis"> total N=256 </span></span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">
<p class="First"><span class="Bold"><span class="Emphasis">7.5 mg/mL </span></span></p>
<span class="Bold"><span class="Emphasis"> total N=297 </span></span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">
<p class="First"><span class="Bold"><span class="Emphasis">10 mg/mL </span></span></p>
<span class="Bold"><span class="Emphasis"> total N=207 </span></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">
<p class="First"><span class="Bold"><span class="Emphasis">5 mg/mL </span></span></p>
<span class="Bold"><span class="Emphasis"> total N=236 </span></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">
<p class="First"><span class="Bold"><span class="Emphasis">7.5 mg/mL </span></span></p>
<span class="Bold"><span class="Emphasis"> total N=174 </span></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<span class="Bold"><span class="Emphasis">  N </span></span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <span class="Bold"><span class="Emphasis">(%)</span></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <span class="Bold"><span class="Emphasis">N</span></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <span class="Bold"><span class="Emphasis">(%)</span></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">N </span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <span class="Bold"><span class="Emphasis">(%)</span></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">N </span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">(%) </span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">N </span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">(%) </span></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"> <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">   99 </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (38.7)</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 146</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (49.2)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">113</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (54.6)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">91</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(38.6)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">89</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(51.1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 34</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (13.3)</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 68</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (22.9)</td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center">41</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(17.4)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">36</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(20.7)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"> <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">  29 </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (11.3)</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 58</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (19.5)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">40</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (19.3)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">32</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(13.6)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">25</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(14.4)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"> <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 18 </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (7)</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 23</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (7.7)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">34</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (16.4)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">21</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(8.9)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">23</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(13.2)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"> <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 18 </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (7)</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 33</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (11.1)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">23</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (11.1)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">19</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(8.1)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">14</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(8)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 12</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (4.7)</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 20</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (6.7)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">16</td>
<td class="Botrule Lrule Rrule Toprule" align="center">  (7.7) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">13</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(5.5)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">9</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(5.2)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 8</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (3.1)</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 5</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (1.7)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">18</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (8.7)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">11</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(4.7)</td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"> <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 6</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (2.3)</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 7</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (2.4)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">6</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (2.9)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">4</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(1.7)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(1.7)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First"> urinary</p>
                 retention</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 5</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (2)</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 8</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (2.7)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (4.8)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(4.2)</td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"> <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 5</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (2)</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 10</td>
<td class="Botrule Lrule Rrule Toprule" align="center">  (3.4) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">5</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (2.4)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">7</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(3)</td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left"> pruritus </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 14</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (4.7)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (1.4)</td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center">7</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(4)</td>
</tr>
</tbody>
</table>
<p>Using data from the same studies, the number (%) of patients experiencing <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> is displayed by patient age, drug and concentration in Table 5.  <br>
    In Table 6, the adverse events for Naropin are broken down by gender.</p>
<table>
<caption><span>Table 5 Effects of Age on <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> (Epidural Administration) Total N: Naropin = 760, bupivacaine = 410 </span></caption>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="6">
<span class="Bold"><span class="Emphasis">Naropin </span></span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="4">
<span class="Bold"><span class="Emphasis"> Bupivacaine </span></span> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">
<span class="Bold"><span class="Emphasis"> AGE </span></span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">
<span class="Bold"><span class="Emphasis">  5 mg/mL </span></span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">
<span class="Bold"><span class="Emphasis">  7.5 mg/mL </span></span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">
<span class="Bold"><span class="Emphasis">  10 mg/mL </span></span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">
<span class="Bold"><span class="Emphasis">5 mg/mL </span></span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">
<span class="Bold"><span class="Emphasis"> 7.5 mg/mL </span></span> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <span class="Bold"><span class="Emphasis">N</span></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<span class="Bold"><span class="Emphasis">(%) </span></span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis"> N </span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<span class="Bold"><span class="Emphasis">(%) </span></span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis"> N </span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<span class="Bold"><span class="Emphasis">(%) </span></span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis"> N </span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<span class="Bold"><span class="Emphasis">(%) </span></span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis"> N </span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<span class="Bold"><span class="Emphasis">(%) </span></span> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"> &lt; 65 </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 68 </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (32.2) </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 99 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  (43.2) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">87 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  (51.5) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  64 </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (33.5) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">73 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  (48.3) </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left"> ≥ 65 </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 31 </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (68.9) </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 47 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  (69.1) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">26 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  (68.4) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  27 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">  (60) </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 16 </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (69.6)</td>
</tr>
</tbody>
</table>
<table>
<caption><span>               Table 6 Most Common Adverse Events by Gender (Epidural Administration) Total N: Females = 405, Males = 355 </span></caption>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold"><span class="Emphasis"> Adverse Reaction </span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><span class="Bold"><span class="Emphasis">  Female  </span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">
<span class="Bold"><span class="Emphasis">  Male </span></span> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <span class="Bold"><span class="Emphasis">N</span></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (<span class="Bold"><span class="Emphasis">%)</span></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <span class="Bold"><span class="Emphasis">N</span></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">( %) </span></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  hypotension </td>
<td class="Botrule Lrule Rrule Toprule" align="center">220</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(54.3)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">138</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (38.9)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  nausea </td>
<td class="Botrule Lrule Rrule Toprule" align="center">119</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(29.4)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">23</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (6.5)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  bradycardia </td>
<td class="Botrule Lrule Rrule Toprule" align="center">65</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(16)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">56</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (15.8)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  vomiting </td>
<td class="Botrule Lrule Rrule Toprule" align="center">59</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(14.6)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">8</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (2.3)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  back pain </td>
<td class="Botrule Lrule Rrule Toprule" align="center">41</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(10.1)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">23</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (6.5)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  headache </td>
<td class="Botrule Lrule Rrule Toprule" align="center">33</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(8.1)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">17</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (4.8)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  chills     </td>
<td class="Botrule Lrule Rrule Toprule" align="center">18</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(4.4)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">5</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (1.4)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  fever </td>
<td class="Botrule Lrule Rrule Toprule" align="center">16</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(4)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (0.8)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  pruritus </td>
<td class="Botrule Lrule Rrule Toprule" align="center">16</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(4)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (0.3)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  pain </td>
<td class="Botrule Lrule Rrule Toprule" align="center">12</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(3)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">4</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (1.1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  urinary retention </td>
<td class="Botrule Lrule Rrule Toprule" align="center">11</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(2.7)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">7</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (2)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  dizziness </td>
<td class="Botrule Lrule Rrule Toprule" align="center">9</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(2.2)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">4</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (1.1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">  hypoesthesia </td>
<td class="Botrule Lrule Rrule Toprule" align="center">8</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(2)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (0.6)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left">  paresthesia </td>
<td class="Botrule Lrule Rrule Toprule" align="center">8</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(2)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> (2.8)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="f9490539-643d-445a-9a2c-17f73b9ca01a"></a><a name="section-9.5"></a><p></p>
<h2>Systemic Reactions</h2>
<p class="First">The most commonly encountered acute adverse experiences that demand immediate countermeasures are related to the central nervous system and the cardiovascular system.  These adverse experiences are generally dose-related and due to high plasma levels that may result from overdosage, rapid absorption from the injection site, diminished tolerance or from unintentional intravascular injection of the local anesthetic solution.  In addition to systemic dose-related toxicity, unintentional subarachnoid injection of drug during the intended performance of lumbar epidural block or nerve blocks near the vertebral column (especially in the head and neck region) may result in underventilation or <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> ("Total or High Spinal").  Also, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> due to loss of sympathetic tone and <span class="product-label-link" type="condition" conceptid="4275136" conceptname="Paralysis of diaphragm">respiratory paralysis</span> or underventilation due to cephalad extension of the motor level of anesthesia may occur.  This may lead to secondary <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> if untreated.  Factors influencing plasma protein binding, such as <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>, systemic diseases that alter protein production or competition with other drugs for protein binding sites, may diminish individual tolerance.<br><br>
    Epidural administration of Naropin has, in some cases, as with other local anesthetics, been associated with transient increases in temperature to &gt;38.5°C.  This occurred more frequently at doses of Naropin &gt;16 mg/h.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="c14d7f84-3614-4a5e-bcce-3944310ff7c9"></a><a name="section-9.6"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">Neurologic Reactions</span></h2>
<p class="First">These are characterized by excitation and/or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.  <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> or <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span> may occur, possibly proceeding to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.  However, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span> may be transient or absent, with <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> being the first manifestation of an adverse reaction.  This may quickly be followed by <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> merging into <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span> and <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>.  Other central nervous system effects may be <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, and constriction of the pupils.<br><br>
    The incidence of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> associated with the use of local anesthetics varies with the route of administration and the total dose administered. In a survey of studies of epidural anesthesia, overt toxicity progressing to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> occurred in approximately 0.1% of local anesthetic administrations.<br><br>
    The incidence of adverse neurological reactions associated with the use of local anesthetics may be related to the total dose and concentration of local anesthetic administered and are also dependent upon the particular drug used, the route of administration, and the physical status of the patient.  Many of these observations may be related to local anesthetic techniques, with or without a contribution from the drug.  During lumbar epidural block, occasional unintentional penetration of the subarachnoid space by the catheter or needle may occur.  Subsequent adverse effects may depend partially on the amount of drug administered intrathecally as well as the physiological and physical effects of a dural puncture.  These observations may include spinal block of varying magnitude (including high or total spinal block), <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> secondary to spinal block, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, loss of bladder and bowel control (fecal and <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>), and loss of perineal sensation and sexual function.  Signs and symptoms of subarachnoid block typically start within 2 to 3 minutes of injection.  Doses of 15 and 22.5 mg of Naropin resulted in sensory levels as high as T5 and T4, respectively.  <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesia</span> started in the sacral dermatomes in 2 to 3 minutes and extended to the T10 level in 10 to 13 minutes and lasted for approximately 2 hours.  Other neurological effects following unintentional subarachnoid administration during epidural anesthesia may include persistent anesthesia, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> of the lower extremities, and loss of sphincter control; all of which may have slow, incomplete or no recovery.  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, septic <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>, <span class="product-label-link" type="condition" conceptid="441130" conceptname="Meningeal irritation">meningismus</span>, slowing of labor, increased incidence of forceps delivery, or cranial nerve palsies due to traction on nerves from loss of cerebrospinal fluid have been reported (see <span class="Bold"><span class="Emphasis"><a href="#f5ebc1d7-2664-4513-83ff-f0620e8e02ef">DOSAGE AND ADMINISTRATION</a></span></span> discussion of Lumbar Epidural Block).  A high spinal is characterized by <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> of the arms, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, <span class="product-label-link" type="condition" conceptid="4275136" conceptname="Paralysis of diaphragm">respiratory paralysis</span> and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="dc2ebf94-fb53-4235-a27a-4634da0b14b7"></a><a name="section-9.7"></a><p></p>
<h2>Cardiovascular System                                     Reactions</h2>
<p class="First">High doses or unintentional intravascular injection may lead to high plasma levels and related <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the myocardium, decreased <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, including <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> and <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>, and possibly <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> (see <span class="Bold"><span class="Emphasis"><a href="#a02f7083-33d6-470f-98e6-d7b8ff56cb60">WARNINGS</a></span></span>, <span class="Bold"><span class="Emphasis"><a href="#f1dcc873-dfff-4c97-a13e-cd57d70204fa">PRECAUTIONS</a></span></span>, and <span class="Bold"><span class="Emphasis"><a href="#ace320ff-63ee-4692-a46a-a39e03da5273">OVERDOSAGE</a></span></span>).</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="f40109e2-adda-45aa-abd3-8af138f93a88"></a><a name="section-9.8"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></h2>
<p class="First">Allergic type reactions are rare and may occur as a result of sensitivity to the local anesthetic (see <span class="Bold"><span class="Emphasis"><a href="#a02f7083-33d6-470f-98e6-d7b8ff56cb60">WARNINGS</a></span></span>).  These reactions are characterized by signs such as <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span> (including <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>), <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, excessive <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, elevated temperature, and possibly, anaphylactoid symptomatology (including severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>).  Cross-sensitivity among members of the amide-type local anesthetic group has been reported.  The usefulness of screening for sensitivity has not been definitively established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ace320ff-63ee-4692-a46a-a39e03da5273"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE:</h1>
<p class="First">Acute emergencies from local anesthetics are generally related to                             high plasma levels encountered, or large doses administered, during                             therapeutic use of local anesthetics or to unintended subarachnoid or                             intravascular injection of local anesthetic solution (see <span class="Bold"><span class="Emphasis"><a href="#a48bb774-07e7-4a8d-9e1d-f6a0731bd93b">  ADVERSE                                         REACTIONS</a></span></span>, <span class="Bold"><span class="Emphasis"><a href="#a02f7083-33d6-470f-98e6-d7b8ff56cb60">  WARNINGS</a></span></span>, and <span class="Bold"><span class="Emphasis"><a href="#f1dcc873-dfff-4c97-a13e-cd57d70204fa">  PRECAUTIONS</a></span></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="b30561b1-dd28-4f46-808b-4eae6fbf8874"></a><a name="section-11"></a><p></p>
<h1>MANAGEMENT OF LOCAL ANESTHETIC EMERGENCIES:</h1>
<p class="First">Therapy with Naropin should be discontinued at the first sign of toxicity.  No specific information is available for the treatment of toxicity with Naropin; therefore, treatment should be symptomatic and supportive.  The first consideration is prevention, best accomplished by incremental injection of Naropin, careful and constant monitoring of cardiovascular and respiratory vital signs and the patient’s state of consciousness after each local anesthetic and during continuous infusion.  At the first sign of change in mental status, oxygen should be administered.<br><br>
    The first step in the management of systemic toxic reactions, as well as underventilation or <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> due to unintentional subarachnoid injection of drug solution, consists of immediate attention to the establishment and maintenance of a patent airway and effective assisted or controlled ventilation with 100% oxygen with a delivery system capable of permitting immediate positive airway pressure by mask.  Circulation should be assisted as necessary.  This may prevent <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> if they have not already occurred.<br><br>
    If necessary, use drugs to control <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. Intravenous barbiturates, anticonvulsant agents, or muscle relaxants should only be administered by those familiar with their use. Immediately after the institution of these ventilatory measures, the adequacy of the circulation should be evaluated.  Supportive treatment of circulatory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> may require administration of intravenous fluids, and, when appropriate, a vasopressor dictated by the clinical situation (such as ephedrine or epinephrine to enhance myocardial contractile force).<br><br>
    Should <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> occur, prolonged resuscitative efforts may be required to improve the probability of a successful outcome.<br><br>
    The mean dosages of ropivacaine producing <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, after intravenous infusion in dogs, nonpregnant and pregnant sheep were 4.9, 6.1 and 5.9 mg/kg, respectively.  These doses were associated with peak arterial total plasma concentrations of 11.4, 4.3 and 5 mcg/mL, respectively.<br><br>
    In human volunteers given intravenous Naropin, the mean (min-max) maximum tolerated total and free arterial plasma concentrations were 4.3 (3.4 to 5.3) and 0.6 (0.3 to 0.9) mcg/mL respectively, at which time moderate CNS symptoms (<span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">muscle twitching</span>) were noted.<br><br>
    Clinical data from patients experiencing local anesthetic induced <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> demonstrated rapid development of <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercarbia</span> and <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> within a minute of the onset of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.  These observations suggest that oxygen consumption and <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> production are greatly increased during local anesthetic <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and emphasize the importance of immediate and effective ventilation with oxygen, which may avoid <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>.<br><br>
    If difficulty is encountered in the maintenance of a patent airway or if prolonged ventilatory support (assisted or controlled) is indicated, endotracheal intubation, employing drugs and techniques familiar to the clinician, may be indicated after initial administration of oxygen by mask.<br><br>
    The supine position is dangerous in pregnant women at term because of aortocaval compression by the gravid uterus.  Therefore, during treatment of systemic toxicity, maternal <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or <span class="product-label-link" type="condition" conceptid="314749" conceptname="Fetal bradycardia">fetal bradycardia</span> following regional block, the parturient should be maintained in the left lateral <span class="product-label-link" type="condition" conceptid="4127794" conceptname="Decubitus">decubitus</span> position if possible, or manual displacement of the uterus off the great vessels should be accomplished.  Resuscitation of obstetrical patients may take longer than resuscitation of nonpregnant patients and closed-chest cardiac compression may be ineffective.  Rapid delivery of the fetus may improve the response to resuscitative efforts.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="f5ebc1d7-2664-4513-83ff-f0620e8e02ef"></a><a name="section-12"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION:</h1>
<p class="First">The rapid injection of a large volume of local anesthetic solution should be avoided and fractional (incremental) doses should always be used.  The smallest dose and concentration required to produce the desired result should be administered.</p>
<p>There have been adverse event reports of <span class="product-label-link" type="condition" conceptid="4345581" conceptname="Chondrolysis of articular cartilage">chondrolysis</span> in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures.  Naropin is not approved for this use (see <span class="Bold"><span class="Emphasis"><a href="#a02f7083-33d6-470f-98e6-d7b8ff56cb60">WARNINGS</a> </span></span>and <span class="Bold"><span class="Emphasis"><a href="#f5ebc1d7-2664-4513-83ff-f0620e8e02ef">DOSAGE AND ADMINISTRATION</a></span></span>).</p>
<p>The dose of any local anesthetic administered varies with the anesthetic procedure, the area to be anesthetized, the vascularity of the tissues, the number of neuronal segments to be blocked, the depth of anesthesia and degree of <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">muscle relaxation</span> required, the duration of anesthesia desired, individual tolerance, and the physical condition of the patient.  Patients in poor general condition due to aging or other compromising factors such as partial or complete heart conduction block, advanced liver disease or severe renal dysfunction require special attention although regional anesthesia is frequently indicated in these patients.  To reduce the risk of potentially serious adverse reactions, attempts should be made to optimize the patient's condition before major blocks are performed, and the dosage should be adjusted accordingly.<br><br>
    Use an adequate test dose (3 to 5 mL of a short-acting local anesthetic solution containing epinephrine) prior to induction of complete block.  This test dose should be repeated if the patient is moved in such a fashion as to have displaced the epidural catheter.  Allow adequate time for onset of anesthesia following administration of each test dose.<br><br>
    Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.  Solutions which are discolored or which contain particulate matter should not be administered.</p>
<a name="a32518f1-5825-4c05-99af-00a32dabb361"></a><table>
<caption><span>Table 7 Dosage Recommendations</span></caption>
<tfoot><tr><td colspan="0" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>= Not Applicable   </dd>
<dt><a name="footnote-3" href="#footnote-reference-3">†</a></dt>
<dd>
<span class="Bold"><span class="Emphasis"></span></span>= The dose for a major nerve block must be adjusted according to site of administration and patient status.  Supraclavicular brachial plexus blocks may be associated with a higher frequency of serious adverse reactions, regardless of the local anesthetic used (see <span class="Bold"><span class="Emphasis"><a href="#f1dcc873-dfff-4c97-a13e-cd57d70204fa">PRECAUTIONS</a></span></span>).   </dd>
<dt><a name="footnote-4" href="#footnote-reference-4">‡</a></dt>
<dd>= Median dose of 21 mg per hour was administered by continuous infusion or by incremental injections (top-ups) over a median delivery time of 5.5 hours.   </dd>
<dt><a name="footnote-5" href="#footnote-reference-5">§</a></dt>
<dd>= Cumulative doses up to 770 mg of Naropin over 24 hours (intraoperative block plus postoperative infusion);  Continuous epidural infusion at rates up to 28 mg per hour for 72 hours have been well tolerated in adults, ie, 2016 mg plus surgical dose of approximately 100 to 150 mg as top-up.   </dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">Conc.</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Volume</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Dose</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Onset</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Duration</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"></td>
<td class="Botrule Lrule Rrule Toprule" align="center">mg/mL</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">mL</td>
<td class="Botrule Lrule Rrule Toprule" align="center">mg</td>
<td class="Botrule Lrule Rrule Toprule" align="center">min</td>
<td class="Botrule Lrule Rrule Toprule" align="center">hours</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left" colspan="7"><span class="Bold"><span class="Emphasis">SURGICAL ANESTHESIA </span></span></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold"><span class="Emphasis">Lumbar Epidural </span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(0.5%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">15 to 30</td>
<td class="Botrule Lrule Rrule Toprule" align="center">75 to 150</td>
<td class="Botrule Lrule Rrule Toprule" align="center">15 to 30</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2 to 4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold"><span class="Emphasis">Administration </span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">7.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(0.75%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">15 to 25</td>
<td class="Botrule Lrule Rrule Toprule" align="center">113 to 188</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10 to 20</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3 to 5</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Surgery</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(1%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">15 to 20</td>
<td class="Botrule Lrule Rrule Toprule" align="center">150 to 200</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10 to 20</td>
<td class="Botrule Lrule Rrule Toprule" align="center">4 to 6</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold"><span class="Emphasis">Lumbar Epidural </span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(0.5%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">20 to 30</td>
<td class="Botrule Lrule Rrule Toprule" align="center">100 to 150</td>
<td class="Botrule Lrule Rrule Toprule" align="center">15 to 25</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2 to 4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold"><span class="Emphasis">Administration </span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">7.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(0.75%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">15 to 20</td>
<td class="Botrule Lrule Rrule Toprule" align="center">113 to 150</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10 to 20</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3 to 5</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Cesarean Section</td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold"><span class="Emphasis">Thoracic Epidural </span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(0.5%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">5 to 15</td>
<td class="Botrule Lrule Rrule Toprule" align="center">25 to 75</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10 to 20</td>
<td class="Botrule Lrule Rrule Toprule" align="center">n/a<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>     </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold"><span class="Emphasis">Administration </span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">7.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(0.75%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">5 to 15</td>
<td class="Botrule Lrule Rrule Toprule" align="center">38 to 113</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10 to 20</td>
<td class="Botrule Lrule Rrule Toprule" align="center">n/a<a href="#footnote-2" class="Sup">*</a>     </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Surgery</td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold"><span class="Emphasis">Major Nerve Block<a name="footnote-reference-3" href="#footnote-3" class="Sup">†</a>      </span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(0.5%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">35 to 50</td>
<td class="Botrule Lrule Rrule Toprule" align="center">175 to 250</td>
<td class="Botrule Lrule Rrule Toprule" align="center">15 to 30</td>
<td class="Botrule Lrule Rrule Toprule" align="center">5 to 8</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">(eg, brachial plexus block)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">7.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(0.75%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10 to 40</td>
<td class="Botrule Lrule Rrule Toprule" align="center">75 to 300</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10 to 25</td>
<td class="Botrule Lrule Rrule Toprule" align="center">6 to 10</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold"><span class="Emphasis">Field Block </span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(0.5%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1 to 40</td>
<td class="Botrule Lrule Rrule Toprule" align="center">5 to 200</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1 to 15</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2 to 6</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">(eg, minor nerve blocks</p>
                and infiltration)</td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left" colspan="7"><span class="Bold"><span class="Emphasis">LABOR <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">PAIN</span> MANAGEMENT </span></span></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold"><span class="Emphasis">Lumbar Epidural Administration </span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Initial Dose</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(0.2%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10 to 20</td>
<td class="Botrule Lrule Rrule Toprule" align="center">20 to 40</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10 to 15</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.5 to 1.5</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">Continuous</p>
                infusion<a name="footnote-reference-4" href="#footnote-4" class="Sup">‡</a>     </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">2</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">(0.2%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">6 to 14</p>
                mL/h</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">12 to 28</p>
                mg/h</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">n/a<a href="#footnote-2" class="Sup">*</a>     </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">n/a<a href="#footnote-2" class="Sup">*</a>     </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">Incremental</p>
                injections (top-up)<a href="#footnote-4" class="Sup">‡</a>     </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">2</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">(0.2%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">10 to 15</p>
                mL/h</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">20 to 30</p>
                mg/h</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">n/a<a href="#footnote-2" class="Sup">*</a>     </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">n/a<a href="#footnote-2" class="Sup">*</a>     </td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left" colspan="7">
<span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">POSTOPERATIVE PAIN</span> MANAGEMENT </span></span> </td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left" colspan="7">
<span class="Bold"><span class="Emphasis">Lumbar Epidural Administration </span></span> </td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">Continuous</p>
                infusion<a name="footnote-reference-5" href="#footnote-5" class="Sup">§</a>      </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">2 </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">(0.2%) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">6 to 14</p>
                mL/h  </td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">12 to 28</p>
                mg/h </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">n/a<a href="#footnote-2" class="Sup">*</a>      </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">n/a<a href="#footnote-2" class="Sup">*</a>      </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First"><span class="Bold"><span class="Emphasis">Thoracic Epidural </span></span></p>
<span class="Bold"><span class="Emphasis">Administration </span></span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">2 </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">(0.2%) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">6 to 14</p>
                mL/h </td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">12 to 28</p>
                mg/h </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">n/a<a href="#footnote-2" class="Sup">*</a>      </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">n/a<a href="#footnote-2" class="Sup">*</a>      </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Continuous infusion<a href="#footnote-5" class="Sup">§</a>      </td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">
<span class="Bold"><span class="Emphasis">Infiltration </span></span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center">2</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(0.2%) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">1 to 100 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">2 to 200 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">1 to 5 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">2 to 6 </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left">(eg, minor nerve block) </td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 5 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">(0.5%) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">1 to 40 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">5 to 200 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">1 to 5 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">2 to 6 </td>
</tr>
</tbody>
</table>
<p>The doses in the table are those considered to be necessary to produce a successful block and should be regarded as guidelines for use in adults.  Individual variations in onset and duration occur.  The figures reflect the expected average dose range needed.  For other local anesthetic techniques standard current textbooks should be consulted.<br><br>
    When prolonged blocks are used, either through continuous infusion or through repeated bolus administration, the risks of reaching a toxic plasma concentration or inducing local neural injury must be considered.  Experience to date indicates that a cumulative dose of up to 770 mg Naropin administered over 24 hours is well tolerated in adults when used for <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">postoperative pain</span> management:  ie, 2016 mg.  Caution should be exercised when administering Naropin for <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span> of time, eg, &gt;70 hours in debilitated patients.<br><br>
    For treatment of <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">postoperative pain</span>, the following technique can be recommended: If regional anesthesia was not used intraoperatively, then an initial epidural block with 5 to 7 mL  Naropin is induced via an epidural catheter.  <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesia</span> is maintained with an infusion of Naropin, 2 mg/mL (0.2%).  Clinical studies have demonstrated that infusion rates of 6 to 14 mL (12 to 28 mg) per hour provide adequate <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> with nonprogressive motor block.  With this technique a significant reduction in the need for opioids was demonstrated.  Clinical experience supports the use of Naropin epidural infusions for up to 72 hours.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="d9f3fb0b-af7c-4f11-b5d3-30bf3041e82a"></a><a name="section-13"></a><p></p>
<h1>HOW SUPPLIED:</h1>
<p class="First"><span class="Bold"><span class="Emphasis">Naropin (ropivacaine HCl Injection, USP) is supplied as follows: </span></span></p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First"><span class="Bold"><span class="Emphasis">Product No. </span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First"><span class="Bold"><span class="Emphasis">NDC No. </span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold"><span class="Emphasis">Strength </span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold"><span class="Emphasis">Size </span></span></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">NP278827</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">63323-288-27</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">1% (10 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left">20 mL plastic ampule packaged in fives.</td>
</tr>
</tbody></table>
<p>Naropin<span class="Sup">®</span> is also available as follows:</p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First"><span class="Bold"><span class="Emphasis">Product No. </span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First"><span class="Bold"><span class="Emphasis">NDC No. </span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold"><span class="Emphasis">Strength </span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold"><span class="Emphasis">Size </span></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">NP278635</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">63323-286-95</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">0.5% (5 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left">30 mL fill, in a 30 mL single dose vial, in packages of 25.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">NP278637</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">63323-286-37</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">0.5% (5 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left">30 mL fill, in a 30 mL single dose vial packaged individually.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">NP278567</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">63323-285-67</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">0.2% (2 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left">100 mL infusion bottle packaged individually.</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left">NP278821 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left">63323-288-29 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left">1% (10 mg/mL) <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left">20 mL fill, in a 20 mL single dose vial, in package of 25. <br>
</td>
</tr>
</tbody></table>
<p>The solubility of ropivacaine is limited at pH above 6.  Thus, care must be taken as precipitation may occur if Naropin is mixed with alkaline solutions.<br><br>
    Disinfecting agents containing heavy metals, which cause release of respective ions (mercury, zinc, copper, etc.) should not be used for skin or mucous membrane disinfection since they have been related to incidents of <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>.<br>
    When chemical disinfection of the container surface is desired, either isopropyl alcohol (91%) or ethyl alcohol (70%) is recommended.  It is recommended that chemical disinfection be accomplished by wiping the ampule or vial stopper thoroughly with cotton or gauze that has been moistened with the recommended alcohol just prior to use.  When a container is required to have a sterile outside, a Sterile-Pak should be chosen.  Glass containers may, as an alternative, be autoclaved once.  Stability has been demonstrated using a targeted F<span class="Sub">0</span> of 7 minutes at 121°C.<br><br>
    Solutions should be stored at 20º to 25°C (68º to 77°F) [see USP Controlled Room Temperature].</p>
<p>This container closure is not made with natural rubber latex.<br><br>
    These products are intended for single use and are free from preservatives. Any solution remaining from an opened container should be discarded promptly.  In addition, continuous infusion bottles should not be left in place for more than 24 hours.<br><br>
    NAROPIN is a trademark of Fresenius Kabi USA, LLC.</p>
<p>N+ and NOVAPLUS are registered trademarks of Novation, LLC. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="db79ef20-7a36-4232-a70d-d9ad659fcca3"></a><a name="section-14"></a><p></p>
<h1></h1>
<p class="First">Manufactured for:</p>
<p><span class="Bold"><span class="Emphasis">Fresenius Kabi USA, LLC</span></span><br>
    Lake Zurich, IL 60047</p>
<p>Made in Norway</p>
<p>451107E/Revised: June 2013</p>
<br><br><p><img alt="logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=56dfabf7-f7a8-4601-b17a-cb16fb995b0f&amp;name=naropin-figure-2-novapluslogo.jpg"> </p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="e31526c1-68b1-4edc-be57-f7df2a419544"></a><a name="section-15"></a><p></p>
<h1></h1>
<span class="Bold"><span class="Emphasis">PACKAGE LABEL - PRINCIPAL DISPLAY - Naropin 20 mL Ampule Label<br></span></span><p class="First"><span class="Bold"><span class="Emphasis">NDC 63323-288-27 </span></span></p>
<p>NP278827</p>
<p><span class="Bold"><span class="Emphasis">Naropin<span class="Sup">® </span>(ropivacaine HCl Injection, USP)<br><br>
    1%  200 mg/20 mL  (10 mg/mL)</span></span></p>
<p>Not for Inhalation.</p>
<p><span class="Bold"><span class="Emphasis">20 mL</span></span> ampule</p>
<p>Rx only<span class="Bold"><span class="Emphasis"> <br></span></span></p>
<p><span class="Bold"><span class="Emphasis"><br></span></span></p>
<p><img alt="np278827-amp" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=56dfabf7-f7a8-4601-b17a-cb16fb995b0f&amp;name=naropin-figure-3-np278827-ampule.jpg"> </p>
<p><span class="Bold"><span class="Emphasis"><br></span></span></p>
<p> </p>
<p><span class="Bold"><span class="Emphasis">PACKAGE LABEL - PRINCIPAL DISPLAY - Naropin 20 mL Ampule Lidding Label<br></span></span></p>
<p><span class="Bold"><span class="Emphasis">NDC 63323-288-27 </span></span></p>
<p>NP278827</p>
<p><span class="Bold"><span class="Emphasis">Naropin<span class="Sup">® </span>(ropivacaine HCl Injection, USP)</span></span></p>
<p><span class="Bold"><span class="Emphasis">Sterile-Pak</span></span></p>
<p><span class="Bold"><span class="Emphasis">1%  200 mg/20 mL  (10 mg/mL)</span></span></p>
<p>For Epidural Administration Only.</p>
<p>Not for Intravenous Administration.</p>
<p><img alt="np278827-ldg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=56dfabf7-f7a8-4601-b17a-cb16fb995b0f&amp;name=naropin-figure-4-np278827-lidding.jpg"> </p>
<p> </p>
<p> </p>
<p><span class="Bold"><span class="Emphasis">PACKAGE LABEL - PRINCIPAL DISPLAY - Naropin 20 mL Ampule Carton Panel<br></span></span></p>
<p><span class="Bold"><span class="Emphasis">NDC 63323-288-27 </span></span></p>
<p>NP278827</p>
<p><span class="Bold"><span class="Emphasis">Naropin<span class="Sup">® </span>(ropivacaine HCl Injection, USP)<br><br>
    1%  200 mg/20 mL  (10 mg/mL)</span></span></p>
<p>For Epidural Administration Only.</p>
<p>Not for Intravenous Administration. </p>
<p>Contains<span class="Bold"><span class="Emphasis"> Five</span></span> Presterilized <span class="Bold"><span class="Emphasis">20 mL</span></span> Plastic Ampule Units</p>
<p><span class="Bold"><span class="Emphasis">Not for Inhalation.</span></span></p>
<p>Rx only</p>
<p> </p>
<p><img alt="np278827-box" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=56dfabf7-f7a8-4601-b17a-cb16fb995b0f&amp;name=naropin-figure-5-np278827-box.jpg"> </p>
<br><p><span class="Bold"><span class="Emphasis"><br></span></span></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NAROPIN 		
					</strong><br><span class="contentTableReg">ropivacaine hydrochloride injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63323-288</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">EPIDURAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ROPIVACAINE HYDROCHLORIDE</strong> (ROPIVACAINE) </td>
<td class="formItem">ROPIVACAINE HYDROCHLORIDE</td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">7.1 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63323-288-27</td>
<td class="formItem">5  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">20 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020533</td>
<td class="formItem">08/04/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Fresenius Kabi USA, LLC
							(608775388)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Fresenius Kabi Norge AS</td>
<td class="formItem"></td>
<td class="formItem">731170932</td>
<td class="formItem">MANUFACTURE(63323-288)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>fa18a249-fd92-4bf9-82b3-df7c0d2bdf62</div>
<div>Set id: 56dfabf7-f7a8-4601-b17a-cb16fb995b0f</div>
<div>Version: 1</div>
<div>Effective Time: 20140320</div>
</div>
</div> <div class="DistributorName">Fresenius Kabi USA, LLC</div></p>
</body></html>
